AbbVie Inc. (ABBV) FY2024 Q3 P&L / Income Statement

AbbVie Inc. (ABBV) FY2024 Q3 P&L / Income Statement

Income statement for 2024-07-01 through 2024-09-30. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenues

14,460,000,000 US dollars

Cost of products sold

4,212,000,000 US dollars

Gross profit (calculated)

10,248,000,000 US dollars

Operating expenses (calculated)

6,417,000,000 US dollars

Operating earnings

3,831,000,000 US dollars

Other income (expense), net (calculated)

negative 1,747,000,000 US dollars

Earnings before income tax expense

2,084,000,000 US dollars

Income tax expense

520,000,000 US dollars

Net earnings

1,564,000,000 US dollars

Aesthetics - Botox Cosmetic

671,000,000 US dollars

Aesthetics - Juvederm Collection

258,000,000 US dollars

Aesthetics - Other Aesthetics

310,000,000 US dollars

Eye Care - Alphagan/Combigan

62,000,000 US dollars

Eye Care - Lumigan/Ganfort

116,000,000 US dollars

Eye Care - Other Eye Care

207,000,000 US dollars

Eye Care - Ozurdex

119,000,000 US dollars

Eye Care - Restasis

21,000,000 US dollars

Hematologic Oncology - Epkinly

43,000,000 US dollars

Hematologic Oncology - Imbruvica

828,000,000 US dollars

Hematologic Oncology - Venclexta

677,000,000 US dollars

Immunology - Humira

2,227,000,000 US dollars

Immunology - Rinvoq

1,614,000,000 US dollars

Immunology - Skyrizi

3,205,000,000 US dollars

Neuroscience - Botox Therapeutic

848,000,000 US dollars

Neuroscience - Duodopa

111,000,000 US dollars

Neuroscience - Other Neuroscience

84,000,000 US dollars

Neuroscience - Qulipta

176,000,000 US dollars

Neuroscience - Ubrelvy

269,000,000 US dollars

Neuroscience - Vraylar

875,000,000 US dollars

Other Key Products - Linzess/Constella

234,000,000 US dollars

Other Key Products - Mavyret

302,000,000 US dollars

Undisclosed (calculated)

1,203,000,000 US dollars

Acquired IPR&D and milestones

82,000,000 US dollars

Research and development

2,130,000,000 US dollars

Selling, general and administrative

4,205,000,000 US dollars

Other operating income

0 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to AbbVie Inc.: $1.56 B; to noncontrolling interests: $3.00 M.